Overview
The Low-Grade Serous Ovarian Cancer (MSK, 2022) study on cBioPortal analyzes 119 LGSOC samples, highlighting that MAPK pathway alterations are frequent, occurring in approximately 60% of cases, with KRAS (31.9%), NRAS (10.9%), and BRAF (9.2%) being the most common mutations. These alterations correlate with improved overall survival (OS) and increased platinum sensitivity.
Key findings from this study include:
- Targeted Pathway: The study highlights the mutational landscape of the MAP kinase pathway (KRAS, NRAS, BRAF, EIF1AX, NF1/2) in LGSOC.
- Clinical Association: MAPK pathway alterations and specifically KRAS mutations are linked to superior overall survival (OS) and higher sensitivity to platinum-based chemotherapy.
- Mutation Frequency: Top altered genes include KRAS (~32%), NRAS (~11%), BRAF (~9%), and EIF1AX (~9%).
- Patient Profile: KRAS mutations are strongly associated with older age at diagnosis, while germline pathogenic mutations (e.g., MUTYH, BAP1, RB1) are rare.
- Clinical Impact: This data supports the use of routine tumor testing to guide targeted therapy selection (e.g., MEK inhibitors) in recurrent LGSOC.
The dataset includes targeted sequencing for 119 patient samples and is detailed in the publication, "MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma," published in Clinical Cancer Research.